WO1996032345A1 - Metered dose inhaler for beclomethasone dipropionate - Google Patents
Metered dose inhaler for beclomethasone dipropionate Download PDFInfo
- Publication number
- WO1996032345A1 WO1996032345A1 PCT/US1996/005009 US9605009W WO9632345A1 WO 1996032345 A1 WO1996032345 A1 WO 1996032345A1 US 9605009 W US9605009 W US 9605009W WO 9632345 A1 WO9632345 A1 WO 9632345A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- inhaler according
- fluorocarbon
- propellant
- drug formulation
- formulation
- Prior art date
Links
- 229940071648 metered dose inhaler Drugs 0.000 title claims abstract description 11
- KUVIULQEHSCUHY-XYWKZLDCSA-N Beclometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O KUVIULQEHSCUHY-XYWKZLDCSA-N 0.000 title abstract description 5
- 229950000210 beclometasone dipropionate Drugs 0.000 title abstract 2
- 239000003380 propellant Substances 0.000 claims abstract description 35
- 229920002313 fluoropolymer Polymers 0.000 claims abstract description 34
- 239000013583 drug formulation Substances 0.000 claims abstract description 30
- NBVXSUQYWXRMNV-UHFFFAOYSA-N fluoromethane Chemical compound FC NBVXSUQYWXRMNV-UHFFFAOYSA-N 0.000 claims abstract description 18
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 15
- 239000012453 solvate Substances 0.000 claims abstract description 11
- 239000013543 active substance Substances 0.000 claims abstract description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical group CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 41
- 239000000203 mixture Substances 0.000 claims description 36
- 238000009472 formulation Methods 0.000 claims description 24
- 150000004682 monohydrates Chemical class 0.000 claims description 19
- 239000004812 Fluorinated ethylene propylene Substances 0.000 claims description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 14
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 claims description 13
- 239000006184 cosolvent Substances 0.000 claims description 13
- 229910052782 aluminium Inorganic materials 0.000 claims description 12
- 239000004094 surface-active agent Substances 0.000 claims description 12
- 239000004813 Perfluoroalkoxy alkane Substances 0.000 claims description 11
- 229920000642 polymer Polymers 0.000 claims description 11
- LVGUZGTVOIAKKC-UHFFFAOYSA-N 1,1,1,2-tetrafluoroethane Chemical group FCC(F)(F)F LVGUZGTVOIAKKC-UHFFFAOYSA-N 0.000 claims description 8
- 229920001343 polytetrafluoroethylene Polymers 0.000 claims description 8
- 239000004810 polytetrafluoroethylene Substances 0.000 claims description 8
- 239000004962 Polyamide-imide Substances 0.000 claims description 7
- 239000004411 aluminium Substances 0.000 claims description 7
- 229910052751 metal Inorganic materials 0.000 claims description 7
- 239000002184 metal Substances 0.000 claims description 7
- 229920002312 polyamide-imide Polymers 0.000 claims description 7
- 150000003839 salts Chemical class 0.000 claims description 7
- 239000002245 particle Substances 0.000 claims description 6
- NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 claims description 5
- 229910045601 alloy Inorganic materials 0.000 claims description 5
- 239000000956 alloy Substances 0.000 claims description 5
- 229960002052 salbutamol Drugs 0.000 claims description 5
- 238000002425 crystallisation Methods 0.000 claims description 4
- 208000023504 respiratory system disease Diseases 0.000 claims description 4
- GIIZNNXWQWCKIB-UHFFFAOYSA-N Serevent Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 GIIZNNXWQWCKIB-UHFFFAOYSA-N 0.000 claims description 3
- 229960004017 salmeterol Drugs 0.000 claims description 3
- TXEYQDLBPFQVAA-UHFFFAOYSA-N tetrafluoromethane Chemical group FC(F)(F)F TXEYQDLBPFQVAA-UHFFFAOYSA-N 0.000 claims description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N dimethylmethane Natural products CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 claims 1
- 238000000576 coating method Methods 0.000 description 30
- 239000003814 drug Substances 0.000 description 29
- 239000011248 coating agent Substances 0.000 description 25
- 229940079593 drug Drugs 0.000 description 23
- 239000007921 spray Substances 0.000 description 19
- 229920009441 perflouroethylene propylene Polymers 0.000 description 14
- 239000000725 suspension Substances 0.000 description 12
- 239000000443 aerosol Substances 0.000 description 11
- 229920011301 perfluoro alkoxyl alkane Polymers 0.000 description 10
- -1 flavorings Substances 0.000 description 8
- 229920002959 polymer blend Polymers 0.000 description 8
- 238000010561 standard procedure Methods 0.000 description 8
- 230000004913 activation Effects 0.000 description 6
- 239000002585 base Substances 0.000 description 6
- 229920006393 polyether sulfone Polymers 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 239000004695 Polyether sulfone Substances 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 229920000840 ethylene tetrafluoroethylene copolymer Polymers 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 239000002260 anti-inflammatory agent Substances 0.000 description 3
- 230000008025 crystallization Effects 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- QHSJIZLJUFMIFP-UHFFFAOYSA-N ethene;1,1,2,2-tetrafluoroethene Chemical group C=C.FC(F)=C(F)F QHSJIZLJUFMIFP-UHFFFAOYSA-N 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 210000001331 nose Anatomy 0.000 description 3
- 238000006116 polymerization reaction Methods 0.000 description 3
- 229920005989 resin Polymers 0.000 description 3
- 239000011347 resin Substances 0.000 description 3
- 230000000241 respiratory effect Effects 0.000 description 3
- 239000010935 stainless steel Substances 0.000 description 3
- 229910001220 stainless steel Inorganic materials 0.000 description 3
- KWGRBVOPPLSCSI-WPRPVWTQSA-N (-)-ephedrine Chemical compound CN[C@@H](C)[C@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WPRPVWTQSA-N 0.000 description 2
- YFMFNYKEUDLDTL-UHFFFAOYSA-N 1,1,1,2,3,3,3-heptafluoropropane Chemical compound FC(F)(F)C(F)C(F)(F)F YFMFNYKEUDLDTL-UHFFFAOYSA-N 0.000 description 2
- 229910000838 Al alloy Inorganic materials 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 239000004952 Polyamide Substances 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 2
- 239000004809 Teflon Substances 0.000 description 2
- 229920006362 Teflon® Polymers 0.000 description 2
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 2
- 239000000730 antalgic agent Substances 0.000 description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 229940124630 bronchodilator Drugs 0.000 description 2
- 239000012458 free base Substances 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 150000005828 hydrofluoroalkanes Chemical class 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- LMOINURANNBYCM-UHFFFAOYSA-N metaproterenol Chemical compound CC(C)NCC(O)C1=CC(O)=CC(O)=C1 LMOINURANNBYCM-UHFFFAOYSA-N 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- 229960002657 orciprenaline Drugs 0.000 description 2
- 229920002647 polyamide Polymers 0.000 description 2
- 238000005507 spraying Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 229910021653 sulphate ion Inorganic materials 0.000 description 2
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 1
- XWTYSIMOBUGWOL-UHFFFAOYSA-N (+-)-Terbutaline Chemical compound CC(C)(C)NCC(O)C1=CC(O)=CC(O)=C1 XWTYSIMOBUGWOL-UHFFFAOYSA-N 0.000 description 1
- AKNNEGZIBPJZJG-MSOLQXFVSA-N (-)-noscapine Chemical compound CN1CCC2=CC=3OCOC=3C(OC)=C2[C@@H]1[C@@H]1C2=CC=C(OC)C(OC)=C2C(=O)O1 AKNNEGZIBPJZJG-MSOLQXFVSA-N 0.000 description 1
- UBLVUWUKNHKCJJ-ZSCHJXSPSA-N (2s)-2,6-diaminohexanoic acid;1,3-dimethyl-7h-purine-2,6-dione Chemical compound NCCCC[C@H](N)C(O)=O.O=C1N(C)C(=O)N(C)C2=C1NC=N2 UBLVUWUKNHKCJJ-ZSCHJXSPSA-N 0.000 description 1
- WRRSFOZOETZUPG-FFHNEAJVSA-N (4r,4ar,7s,7ar,12bs)-9-methoxy-3-methyl-2,4,4a,7,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-7-ol;hydrate Chemical compound O.C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC WRRSFOZOETZUPG-FFHNEAJVSA-N 0.000 description 1
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 1
- SRJAWIYPQUNMKC-UHFFFAOYSA-N 2-(3-tridecoxypropoxyphosphanyloxy)ethanamine Chemical compound CCCCCCCCCCCCCOCCCOPOCCN SRJAWIYPQUNMKC-UHFFFAOYSA-N 0.000 description 1
- YREYLAVBNPACJM-UHFFFAOYSA-N 2-(tert-butylamino)-1-(2-chlorophenyl)ethanol Chemical compound CC(C)(C)NCC(O)C1=CC=CC=C1Cl YREYLAVBNPACJM-UHFFFAOYSA-N 0.000 description 1
- LSLYOANBFKQKPT-DIFFPNOSSA-N 5-[(1r)-1-hydroxy-2-[[(2r)-1-(4-hydroxyphenyl)propan-2-yl]amino]ethyl]benzene-1,3-diol Chemical compound C([C@@H](C)NC[C@H](O)C=1C=C(O)C=C(O)C=1)C1=CC=C(O)C=C1 LSLYOANBFKQKPT-DIFFPNOSSA-N 0.000 description 1
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical class O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 1
- 229930003347 Atropine Natural products 0.000 description 1
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 229930186147 Cephalosporin Natural products 0.000 description 1
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 1
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 1
- 229910000881 Cu alloy Inorganic materials 0.000 description 1
- IJVCSMSMFSCRME-KBQPJGBKSA-N Dihydromorphine Chemical compound O([C@H]1[C@H](CC[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O IJVCSMSMFSCRME-KBQPJGBKSA-N 0.000 description 1
- 229920001780 ECTFE Polymers 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 102400000321 Glucagon Human genes 0.000 description 1
- 108060003199 Glucagon Proteins 0.000 description 1
- 229920006360 Hostaflon Polymers 0.000 description 1
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- HUYWAWARQUIQLE-UHFFFAOYSA-N Isoetharine Chemical compound CC(C)NC(CC)C(O)C1=CC=C(O)C(O)=C1 HUYWAWARQUIQLE-UHFFFAOYSA-N 0.000 description 1
- ZCVMWBYGMWKGHF-UHFFFAOYSA-N Ketotifene Chemical compound C1CN(C)CCC1=C1C2=CC=CC=C2CC(=O)C2=C1C=CS2 ZCVMWBYGMWKGHF-UHFFFAOYSA-N 0.000 description 1
- 241001490312 Lithops pseudotruncatella Species 0.000 description 1
- 208000026344 Nasal disease Diseases 0.000 description 1
- 229920006367 Neoflon Polymers 0.000 description 1
- 229920000459 Nitrile rubber Polymers 0.000 description 1
- 208000030880 Nose disease Diseases 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- VQDBNKDJNJQRDG-UHFFFAOYSA-N Pirbuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=N1 VQDBNKDJNJQRDG-UHFFFAOYSA-N 0.000 description 1
- 229920006361 Polyflon Polymers 0.000 description 1
- 239000004642 Polyimide Substances 0.000 description 1
- 229920000265 Polyparaphenylene Polymers 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 229920006355 Tefzel Polymers 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- DXEXNWDGDYUITL-FXSSSKFRSA-N Tipredane Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1CC[C@@](SC)(SCC)[C@@]1(C)C[C@@H]2O DXEXNWDGDYUITL-FXSSSKFRSA-N 0.000 description 1
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 1
- 150000001241 acetals Chemical class 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- AKNNEGZIBPJZJG-UHFFFAOYSA-N alpha-noscapine Natural products CN1CCC2=CC=3OCOC=3C(OC)=C2C1C1C2=CC=C(OC)C(OC)=C2C(=O)O1 AKNNEGZIBPJZJG-UHFFFAOYSA-N 0.000 description 1
- XSDQTOBWRPYKKA-UHFFFAOYSA-N amiloride Chemical compound NC(=N)NC(=O)C1=NC(Cl)=C(N)N=C1N XSDQTOBWRPYKKA-UHFFFAOYSA-N 0.000 description 1
- 229960002576 amiloride Drugs 0.000 description 1
- 229960003556 aminophylline Drugs 0.000 description 1
- FQPFAHBPWDRTLU-UHFFFAOYSA-N aminophylline Chemical compound NCCN.O=C1N(C)C(=O)N(C)C2=C1NC=N2.O=C1N(C)C(=O)N(C)C2=C1NC=N2 FQPFAHBPWDRTLU-UHFFFAOYSA-N 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 230000000954 anitussive effect Effects 0.000 description 1
- 230000002744 anti-aggregatory effect Effects 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000000043 antiallergic agent Substances 0.000 description 1
- 229940065524 anticholinergics inhalants for obstructive airway diseases Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 229960005475 antiinfective agent Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000003434 antitussive agent Substances 0.000 description 1
- 229940124584 antitussives Drugs 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 1
- 229960000396 atropine Drugs 0.000 description 1
- IWLBIFVMPLUHLK-UHFFFAOYSA-N azane;formaldehyde Chemical compound N.O=C IWLBIFVMPLUHLK-UHFFFAOYSA-N 0.000 description 1
- 229940092705 beclomethasone Drugs 0.000 description 1
- 229940098032 beconase Drugs 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000000168 bronchodilator agent Substances 0.000 description 1
- 229960004436 budesonide Drugs 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 229940124587 cephalosporin Drugs 0.000 description 1
- 150000001780 cephalosporins Chemical class 0.000 description 1
- 239000013043 chemical agent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960003821 choline theophyllinate Drugs 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 239000008199 coating composition Substances 0.000 description 1
- 229960004126 codeine Drugs 0.000 description 1
- OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Natural products C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 229960004544 cortisone Drugs 0.000 description 1
- 229940109248 cromoglycate Drugs 0.000 description 1
- IMZMKUWMOSJXDT-UHFFFAOYSA-N cromoglycic acid Chemical compound O1C(C(O)=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C(O)=O)O2 IMZMKUWMOSJXDT-UHFFFAOYSA-N 0.000 description 1
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- HSUGRBWQSSZJOP-RTWAWAEBSA-N diltiazem Chemical compound C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CCN(C)C)C2=CC=CC=C2S1 HSUGRBWQSSZJOP-RTWAWAEBSA-N 0.000 description 1
- 229960004166 diltiazem Drugs 0.000 description 1
- IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- DLNKOYKMWOXYQA-UHFFFAOYSA-N dl-pseudophenylpropanolamine Natural products CC(N)C(O)C1=CC=CC=C1 DLNKOYKMWOXYQA-UHFFFAOYSA-N 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 229960002179 ephedrine Drugs 0.000 description 1
- OFKDAAIKGIBASY-VFGNJEKYSA-N ergotamine Chemical compound C([C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@@](C(N21)=O)(C)NC(=O)[C@H]1CN([C@H]2C(C3=CC=CC4=NC=C([C]34)C2)=C1)C)C1=CC=CC=C1 OFKDAAIKGIBASY-VFGNJEKYSA-N 0.000 description 1
- 229960004943 ergotamine Drugs 0.000 description 1
- XCGSFFUVFURLIX-UHFFFAOYSA-N ergotaminine Natural products C1=C(C=2C=CC=C3NC=C(C=23)C2)C2N(C)CC1C(=O)NC(C(N12)=O)(C)OC1(O)C1CCCN1C(=O)C2CC1=CC=CC=C1 XCGSFFUVFURLIX-UHFFFAOYSA-N 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- HQQADJVZYDDRJT-UHFFFAOYSA-N ethene;prop-1-ene Chemical group C=C.CC=C HQQADJVZYDDRJT-UHFFFAOYSA-N 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- 229960001022 fenoterol Drugs 0.000 description 1
- 229960002428 fentanyl Drugs 0.000 description 1
- IVLVTNPOHDFFCJ-UHFFFAOYSA-N fentanyl citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 IVLVTNPOHDFFCJ-UHFFFAOYSA-N 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 229960000676 flunisolide Drugs 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 239000004811 fluoropolymer Substances 0.000 description 1
- 229960002714 fluticasone Drugs 0.000 description 1
- MGNNYOODZCAHBA-GQKYHHCASA-N fluticasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(O)[C@@]2(C)C[C@@H]1O MGNNYOODZCAHBA-GQKYHHCASA-N 0.000 description 1
- 229960002848 formoterol Drugs 0.000 description 1
- BPZSYCZIITTYBL-UHFFFAOYSA-N formoterol Chemical compound C1=CC(OC)=CC=C1CC(C)NCC(O)C1=CC=C(O)C(NC=O)=C1 BPZSYCZIITTYBL-UHFFFAOYSA-N 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
- 229960004666 glucagon Drugs 0.000 description 1
- 125000003104 hexanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 238000002664 inhalation therapy Methods 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- OEXHQOGQTVQTAT-JRNQLAHRSA-N ipratropium Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)[N@@+]2(C)C(C)C)C(=O)C(CO)C1=CC=CC=C1 OEXHQOGQTVQTAT-JRNQLAHRSA-N 0.000 description 1
- 229960001888 ipratropium Drugs 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 229960001268 isoetarine Drugs 0.000 description 1
- 229960001317 isoprenaline Drugs 0.000 description 1
- 229960004958 ketotifen Drugs 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- HNJJXZKZRAWDPF-UHFFFAOYSA-N methapyrilene Chemical compound C=1C=CC=NC=1N(CCN(C)C)CC1=CC=CS1 HNJJXZKZRAWDPF-UHFFFAOYSA-N 0.000 description 1
- 229960001869 methapyrilene Drugs 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- PLPRGLOFPNJOTN-UHFFFAOYSA-N narcotine Natural products COc1ccc2C(OC(=O)c2c1OC)C3Cc4c(CN3C)cc5OCOc5c4OC PLPRGLOFPNJOTN-UHFFFAOYSA-N 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- 229960004398 nedocromil Drugs 0.000 description 1
- RQTOOFIXOKYGAN-UHFFFAOYSA-N nedocromil Chemical compound CCN1C(C(O)=O)=CC(=O)C2=C1C(CCC)=C1OC(C(O)=O)=CC(=O)C1=C2 RQTOOFIXOKYGAN-UHFFFAOYSA-N 0.000 description 1
- 229920006120 non-fluorinated polymer Polymers 0.000 description 1
- 229960004708 noscapine Drugs 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- NVOYVOBDTVTBDX-PMEUIYRNSA-N oxitropium Chemical compound CC[N+]1(C)[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)C1=CC=CC=C1 NVOYVOBDTVTBDX-PMEUIYRNSA-N 0.000 description 1
- 229960000797 oxitropium Drugs 0.000 description 1
- RLANKEDHRWMNRO-UHFFFAOYSA-M oxtriphylline Chemical compound C[N+](C)(C)CCO.O=C1N(C)C(=O)N(C)C2=C1[N-]C=N2 RLANKEDHRWMNRO-UHFFFAOYSA-M 0.000 description 1
- 150000002960 penicillins Chemical class 0.000 description 1
- XDRYMKDFEDOLFX-UHFFFAOYSA-N pentamidine Chemical compound C1=CC(C(=N)N)=CC=C1OCCCCCOC1=CC=C(C(N)=N)C=C1 XDRYMKDFEDOLFX-UHFFFAOYSA-N 0.000 description 1
- 229960004448 pentamidine Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229960001802 phenylephrine Drugs 0.000 description 1
- SONNWYBIRXJNDC-VIFPVBQESA-N phenylephrine Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 description 1
- 229960000395 phenylpropanolamine Drugs 0.000 description 1
- DLNKOYKMWOXYQA-APPZFPTMSA-N phenylpropanolamine Chemical compound C[C@@H](N)[C@H](O)C1=CC=CC=C1 DLNKOYKMWOXYQA-APPZFPTMSA-N 0.000 description 1
- 229960005414 pirbuterol Drugs 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920001721 polyimide Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- MIXMJCQRHVAJIO-TZHJZOAOSA-N qk4dys664x Chemical compound O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O MIXMJCQRHVAJIO-TZHJZOAOSA-N 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 229960002720 reproterol Drugs 0.000 description 1
- WVLAAKXASPCBGT-UHFFFAOYSA-N reproterol Chemical compound C1=2C(=O)N(C)C(=O)N(C)C=2N=CN1CCCNCC(O)C1=CC(O)=CC(O)=C1 WVLAAKXASPCBGT-UHFFFAOYSA-N 0.000 description 1
- 229960001457 rimiterol Drugs 0.000 description 1
- IYMMESGOJVNCKV-SKDRFNHKSA-N rimiterol Chemical compound C([C@@H]1[C@@H](O)C=2C=C(O)C(O)=CC=2)CCCN1 IYMMESGOJVNCKV-SKDRFNHKSA-N 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- 229940065721 systemic for obstructive airway disease xanthines Drugs 0.000 description 1
- 229960000195 terbutaline Drugs 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 229940040944 tetracyclines Drugs 0.000 description 1
- BFKJFAAPBSQJPD-UHFFFAOYSA-N tetrafluoroethene Chemical group FC(F)=C(F)F BFKJFAAPBSQJPD-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229920001187 thermosetting polymer Polymers 0.000 description 1
- 239000005028 tinplate Substances 0.000 description 1
- 229950001669 tipredane Drugs 0.000 description 1
- 229960002117 triamcinolone acetonide Drugs 0.000 description 1
- YNDXUCZADRHECN-JNQJZLCISA-N triamcinolone acetonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O YNDXUCZADRHECN-JNQJZLCISA-N 0.000 description 1
- 229960000859 tulobuterol Drugs 0.000 description 1
- 229950000339 xinafoate Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/009—Inhalators using medicine packages with incorporated spraying means, e.g. aerosol cans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
- B65D83/00—Containers or packages with special means for dispensing contents
- B65D83/14—Containers or packages with special means for dispensing contents for delivery of liquid or semi-liquid contents by internal gaseous pressure, i.e. aerosol containers comprising propellant for a product delivered by a propellant
- B65D83/44—Valves specially adapted therefor; Regulating devices
- B65D83/52—Valves specially adapted therefor; Regulating devices for metering
- B65D83/54—Metering valves ; Metering valve assemblies
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
- B65D83/00—Containers or packages with special means for dispensing contents
- B65D83/14—Containers or packages with special means for dispensing contents for delivery of liquid or semi-liquid contents by internal gaseous pressure, i.e. aerosol containers comprising propellant for a product delivered by a propellant
- B65D83/75—Aerosol containers not provided for in groups B65D83/16 - B65D83/74
- B65D83/752—Aerosol containers not provided for in groups B65D83/16 - B65D83/74 characterised by the use of specific products or propellants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/02—General characteristics of the apparatus characterised by a particular materials
- A61M2205/0222—Materials for reducing friction
Definitions
- Aerosol drug formulations Drugs for treating respiratory and nasal disorders are frequently administered in aerosol formulations through the mouth or nose.
- One widely used method for dispensing such aerosol drug formulations involves making a suspension formulation of the drug as a finely divided powder in a liquefied gas known as a propellant.
- the suspension is stored in a sealed container capable of withstanding the pressure required to maintain the propellant as a liquid.
- the suspension is dispersed by activation of a dose metering valve affixed to the container.
- a metering valve may be designed to consistently release a fixed, predetermined mass of the drug formulation upon each activation.
- the propellant rapidly vaporizes leaving a fast moving cloud of very fine particles of the drug formulation.
- This cloud of particles is directed into the nose or mouth of the patient by a channelling device such as a cylinder or open ended cone.
- a channelling device such as a cylinder or open ended cone.
- the patient inhales the drug particles into the lungs or nasal cavity.
- Systems of dispensing drugs in this way are known as "metered dose inhalers" (MDI's). See Peter Byron, Respiratory Drug Delivery, CRC Press, Boca Raton, FL (1990) for a general background on this form of therapy.
- hydrofluoroalkane also known as simply "fluorocarbon" propellant systems, e.g., P134a and P227, under development in recent years to replace chlorofluorocarbons such as P11 , P114, and P12.
- a metered dose inhaler having part or all of its internal metallic surfaces coated with one or more fluorocarbon polymers, optionally in combination with one or more non-fiuorocarbon polymers, for dispensing an inhalation drug formulation comprising beciomethasone dipropionate or a physiologically acceptable solvate thereof, and a fluorocarbon propellant, optionally in combination with one or more other pharmacologically active agents or one or more excipients.
- MDI tered dose inhaler
- MDI system also includes a suitable channelling device.
- MDI can means the container without the cap and valve.
- drug metering valve or “MDI valve” refers to a valve and its associated mechanisms which delivers a predetermined amount of drug formulation from an MDI upon each activation.
- the channelling device may comprise, for example, an actuating device for the valve and a cylindrical or cone-like passage through which medicament may be delivered from the filled MDI can via the MDI valve to the nose or mouth of a patient, e.g. a mouthpiece actuator.
- drug formulation means beciomethasone dipropionate (or a physiologically acceptable solvate thereof) optionally in combination with one or more other pharmacologically active agents such as other antiinflammatory agents, analgesic agents or other respiratory drugs and optionally containing one or more excipients.
- excipients as used herein mean chemical agents having little or no pharmacological activity (for the quantities used) but which enhance the drug formulation or the performance of the MDI system.
- excipients include but are not limited to surfactants, preservatives, flavorings, antioxidants, antiaggregating agents, and cosolvents, e.g., ethanol and diethyl ether.
- Suitable surfactants are generally known in the art, for example, those surfactants disclosed in European Patent Application No. 0327777.
- the amount of surfactant employed is desirable in the range of 0.0001% to 50% weight to weight ratio relative to the drug, in particular, 0.05 to 5% weight to weight ratio.
- a particularly useful- surfactant is 1 ,2-di[7-(F-hexyl) hexanoyl]-glycero-3-phospho- N.N.N-trimethylethanolamine also know as 3, 5, 9-trioxa-4-phosphadocosan-1- aminium, 17, 17, 18,18,19, 19, 20, 20, 21, 21, 22, 22, 22-tridecafluoro-7-[(8, 8, 9, 9,10, 10, 11, 11, 12, 12, 13, 13, 13-tridecafluoro-1-oxotridecyl)oxy]-4-hydroxy-N, N, N-trimethyl-10-oxo-, inner salt,.4-oxide.
- a polar cosolvent such as C 2-6 aliphatic alcohols and polyols eg ethanol, isopropanol and propylene glycol, and preferably ethanol, may be included in the drug formulation in the desired amount, either as the only excipient or in addition to other excipients such as surfactants.
- the drug formulation may contain 0.01 to 5% w/w based on the propellant of a polar cosolvent eg ethanol, preferably 0.1 to 5% w/w e.g. 0.1 to 1% w/w.
- the drug formulation for use in the invention may, if desired, contain beciomethasone dipropionate (or a physiologically acceptable solvate thereof) in combination with one or more other pharmacologically active agents.
- Such medicaments may be selected from any suitable drug useful in inhalation therapy.
- Appropriate medicaments may thus be selected from, for example, analgesics, e.g. codeine, dihydromorphine, ergotamine, fentanyl or morphine; anginal preparations, e.g. diltiazem; antiallergics, e.g. cromoglycate, ketotifen or nedocromil; antiinfectives e.g.
- cephalosporins cephalosporins, penicillins, streptomycin, sulphonamides, tetracyclines and pentamidine
- antihistamines e.g. methapyrilene
- anti-inflammatories e.g. fluticasone (e.g. the propionate), flunisolide, budesonide, tipredane or triamcinolone acetonide
- antitussives e.g. noscapine
- bronchodilators e.g.
- the medicaments may be used in the form of salts (e.g. as alkali metal or amine salts or as acid addition salts) or as esters (e.g.
- solvates e.g. hydrates
- Particularly preferred drug formulations contain beciomethasone dipropionate (or a physiologically acceptable solvate thereof) in combination with a bronchodilator such as salbutamol (e.g. as the free base or the sulphate salt) or salmeterol (e.g. as the xinafoate salt).
- a bronchodilator such as salbutamol (e.g. as the free base or the sulphate salt) or salmeterol (e.g. as the xinafoate salt).
- Propellants used herein mean pharmacologically inert liquids with boiling points from about room temperature (25°C) to about -25°C which singly or in combination exert a high vapor pressure at room temperature.
- the high vapor pressure of the propellant in the MDI forces a metered amount of drug formulation out through the metering valve then the propellant very rapidly vaporizes dispersing the drug particles.
- the propellants used in the present invention are low boiling fluorocarbons; in particular, 1,1,1,2- tetrafluoroethane also known as “propellant 134a” or “P134a” and 1,1 ,1,2,3,3,3- heptafluoropropane also know as “propellant 227” or "P 227”.
- Drug formulations for use in the invention may be free or substantially free of formulation excipients e.g. surfactants and cosolvents etc. Such drug formulations are advantageous since they may be substantially taste and odour free, less irritant and less toxic than excipient-containing formulations.
- a preferred drug formulation consists essentially of beciomethasone dipropionate (or a physiologically acceptable solvate thereof), optionally in combination with one or more other pharmacologically active agents particularly salbutamol (or a physiologically acceptable salt thereof), and a fluorocarbon propellant.
- Preferred propellants are 1 ,1,1 ,2-tetraf luoroethane, 1,1,1 ,2,3,3,3-heptaf luoro-n-propane or mixtures thereof, and especially 1,1,1 ,2-tetrafluoroethane.
- the MDI can and cap are made of aluminum or an alloy of aluminum, although other metals not affected by the drug formulation, such as stainless steel, an alloy of copper, or tin plate, may be used.
- An MDI can may also be fabricated from glass or plastic.
- the MDI cans employed in the present invention are made of aluminium or an alloy thereof.
- strengthened aluminium or aluminum alloy MDI cans may be employed. Such strengthened MDI cans are capable of withstanding particularly stressful coating and curing conditions, e.g. particularly high temperatures, which may be required for certain fluorocarbon polymers.
- MDI cans having an ellipsoidal base offer the further advantage of facilitating the coating process.
- the drug metering valve consists of parts usually made of stainless steel, a pharmacologically inert and propellant resistant polymer, such as acetal, polyamide (e.g., Nylon ® ), polycarbonate, polyester, fluorocarbon polymer (e.g., Teflon*) or a combination of these materials. Additionally, seals and "O" rings of various materials (e.g., nitrile rubbers, polyurethane, acetyl resin, fluorocarbon polymers), or other elastomeric materials are employed in and around the valve.
- a pharmacologically inert and propellant resistant polymer such as acetal, polyamide (e.g., Nylon ® ), polycarbonate, polyester, fluorocarbon polymer (e.g., Teflon*) or a combination of these materials.
- seals and "O" rings of various materials e.g., nitrile rubbers, polyurethane, acetyl resin, fluor
- Fluorocarbon polymers for use in the invention include fluorocarbon polymers which are made of multiples of one or more of the following monomeric units: tetrafluoroethylene (PTFE), fluorinated ethylene propylene (FEP), perfluoroalkoxyalkane (PFA), ethylene tetrafluoroethylene (ETFE), vinyldienefluoride (PVDF), and chlorinated ethylene tetrafluoroethylene.
- the fluorinated polymer may be blended with non-fluorinated polymers such as polyamides, polyimides, polyethersulfones, polyphenylene su If ides and amine- formaldehyde thermosetting resins. These added polymers improve adhesion of the polymer coating to the can walls.
- Preferred polymer blends are PTFE/FEP/polyamideimide, PTFE/polyethersulphone (PES) and FEP- benzoguanamine.
- Particularly preferred coatings are pure PFA, FEP and blends of PTFE and polyethersulphone (PES). Fluorocarbon polymers are marketed under trademarks such as Teflon*, Tefzel*. Halar* , Hostaflon*. Polyflon* and Neoflon*. Grades of polymer include FEP DuPont 856-200, PFA DuPont 857-200, PTFE-PES DuPont 3200-100, PTFE- FEP-polyamideimide DuPont 856P23485, FEP powder DuPont 532 and PFA Hoechst 6900n.
- the coating thickness is in the range of about 1 ⁇ m to about 1mm. Suitably the coating thickness is in the range of about 1 ⁇ m to about 100 ⁇ m, e.g. 1 ⁇ m to 25 ⁇ m. Coatings may be applied in one or more coats.
- the fluorocarbon polymers for use in the invention are coated onto MDI cans made of metal, especially MDI cans made of aluminium or an alloy thereof.
- the particle size of the particular (e.g., micronised) drug should be such as to permit inhalation of substantially all the drug into the lungs upon administration of the aerosol formulation and will thus be less than 100 microns, desirably less than microns, and, in particular, in the range of 1-10 microns, e.g., 1-5 microns.
- the final aerosol formulation desirably contains 0.005-10% weight to weight ratio, in particular 0.005-5% weight to weight ratio, especially 0.01-1.0% weight to weight ratio, of drug relative to the total weight of the formulation.
- a further aspect of the present invention is a metered dose inhaler having part or all of its internal metallic surfaces coated with one or more fluorocarbon polymers, optionally in combination with one or more fluorocarbon polymers, for dispersing an inhalation drug formulation comprising beciomethasone dipropionate and a fluorocarbon propellant optionally in combination with one or more other pharmacologically active agents and one or more excipients.
- a particular formulation for use in the metered dose inhaler of the present invention comprises: (a) beciomethasone dipropionate monohydrate, the particle size of substantially all the monohydrate being less than 20 microns;
- Such aerosol formulations desirably contain at least 0.015% (e.g., 0.015 to 0.1%) by weight of the formulation of water (excluding the water of crystallization associated with the beciomethasone dipropionate monohydrate), preferably at least 0.02%, for example 0.025% by weight or more of added water.
- Preferred formulations according to the invention contain at least 0.026%, for example 0.026 to 0.08% by weight of water, in addition to the water of crystallization associated with the beciomethasone dipropionate monohydrate.
- a cosolvent such as ethanol may be included in the formulation in the desired amount.
- the formulation may contain 0.05 to 3.0% w/w based on the propellant of a polar cosolvent such as ethanol.
- a polar cosolvent such as ethanol.
- the fluorocarbon propellant is 1,1,1 ,2-tetraf luoroethane, 1,1,1,2,3,3,3-heptaf luoro-n-propane or mixtures thereof, and especially 1,1,1,2-tetraf luoroethane.
- a further formulation comprises or consists essentially of beciomethasone dipropionate or a physiologically acceptable solvate thereof, optionally in combination with one or more other pharmacologically active agents, a fluorocarbon propellant and 0.01 to 0.05% w/w based on the propellant of a polar cosolvent such as ethanol, which formulation is free of surfactant.
- a polar cosolvent such as ethanol
- the propellant is 1,1,1,2-tetraf luoroethane or 1,1,1,2,3,3,3- heptafluoro-n-propane, although mixtures thereof may also be used.
- a particular aspect of the present invention is an MDI having part or essentially all of its internal surfaces e.g. metallic surfaces coated with PFA or FEP, or blended fluoropolymer resin systems such as PTFE-PES with or without a proper coat of polyamideimide or polyethersulfone for dispersing a drug formulation as defined hereinabove.
- the MDI can is made of aluminum or an alloy thereof.
- the MDI can be coated by the means known in the art of metal coating.
- a metal such as aluminum or stainless steel, may be precoated as coil stock and cured before being stamped or drawn into the can shape. This method is well is suited to high volume production for two reasons. First, the art of coating coil stock is well developed and several manufacturers can custom coat metal coil stock to high standards of uniformity and in a wide range of thicknesses. Second, the precoated stock can be stamped or drawn at high speeds and precision by essentially the same methods used to draw or stamp uncoated stock.
- coated cans are by electrostatic dry powder coating or by spraying preformed MDI cans inside with formulations of the coating fluorinated polymer/polymer blend and then curing.
- the preformed MDI cans may also be dipped in the fluorocarbon polymer/polymer blend coating formulation and cured, thus becoming coated on the inside and out.
- the fluorocarbon polymer/polymer blend formulation may also be poured inside the MDI cans then drained out leaving the insides with the polymer coat.
- preformed MDI cans are spray-coated with the fluorinated polymer/polymer blend.
- the fluorocarbon polymer/polymer blend may also be formed in situ at the can walls using plasma polymerization of the fluorocarbon monomers. Fluorocarbon polymer film may be blown inside the MDI cans to form bags.
- fluorocarbon polymers such as ETFE, FEP, and PTFE are available as film stock.
- the appropriate curing temperature is dependent on the fluorocarbon polymer/polymer blend chosen for the coating and the coating method employed. However, for coil coating and spray coating temperatures in excess of the melting point of the polymer are typically required, for example, about 50° C above the melting point for up to about 20 minutes such as about 5 to 10 minutes eg about 8 minutes or as required.
- curing temperatures in the range of about 300°C to about 400°C, e.g. about 350°C to 380°C are suitable.
- temperatures in the range of about 20°C to about 100°C may be employed.
- the fluorocarbon polymer may also be formed in situ at the can walls using plasma polymerization of the fluorocarbon monomers. Fluorocarbon polymer film may be blown inside the MDI cans to form bags.
- fluorocarbon polymers such as ETFE, FEP, and PTFE are available as film stock.
- the MDI's taught herein may be prepared by methods of the art (e.g., see Byron, above and U.S. patent 5,345,980) substituting conventional cans for those coated with a fluorinated polymer. That is, beciomethasone dipropionate and other components of the formulation are filled into an aerosol can coated with a fluorinated polymer. The can is fitted with a cap assembly which is crimped in place. The suspension of the drug in the fluorocarbon propellant in liquid form may be introduced through the metering valve as taught in U.S. 5,345,980 incorporated herein by reference.
- the MDI's with fluorocarbon coated interiors taught herein may be used in medical practice in a similar manner as non-coated MDI's now in clinical use.
- the MDI's taught herein are particularly useful for containing and dispensing inhaled drug formulations with hydrofluoroalkane fluorocarbon propellants such as 134a with little, or essentially no, excipient and which tend to deposit or cling to the interior walls and parts of the MDI system.
- hydrofluoroalkane fluorocarbon propellants such as 134a
- it is advantageous to dispense an inhalation drug with essentially no excipient e.g., where the patient may be allergic to an excipient or the drug reacts with an excipient.
- MDI's containing the formulations described hereinabove, MDI systems and the use of such MDI systems for the treatment of respiratory disorders e.g. asthma comprise further aspects of the present invention.
- Standard 0.46 mm thick aluminum sheet (United Aluminum) was spray-coated (DuPont, Wilmington, DE) with FEP (DuPont 856-200) and cured. This sheet was then deep-drawn into cans (Presspart Inc., Cary, NC). The thickness of the coating is approximately 10 ⁇ m to 50 ⁇ m. These cans are then purged of air, the valves crimped in place, and a suspension of about 60 mg beciomethasone dipropionate in about 18 gm P134A is filled through the valve.
- Standard 12.5 ml MDI cans Pressurepart Inc., Cary NC
- PTFE-PES blend DuPont
- the thickness of the coating is between approximately 1 ⁇ m and approximately 20 ⁇ m.
- These cans are then purged of air, the valves crimped in place, and a suspension of about 68mg micronised beciomethasone dipropionate monohydrate in about 6.1 mg water and about 18.2g P134a is filled through the valve.
- Standard 12.5ml MDI cans Pressurepart Inc., Cary NC
- PTFE-FEP-polyamideimide blend DuPont
- the thickness of the coating is between approximately 1 ⁇ m and approximately 20 ⁇ m.
- Standard 12.5ml MDI cans Pressurepart Inc., Cary NC
- FEP powder DuPont FEP 532
- the thickness of the coating is between approximately 1 ⁇ m and approximately 20 ⁇ m.
- Standard 0.46mm thick aluminium sheet is spray coated with FEP- Benzoguanamine and cured. This sheet is then deep-drawn into cans. These cans are then purged of air, the valves crimped in place, and a suspension of about 68mg micronised beciomethasone dipropionate monohydrate in about 6.1mg water and about 18.2g P134a is filled through the valve.
- Standard 12.5 ml MDI cans Pressurepart Inc., Cary NC
- PFA Hoechst PFA-6900n
- the thickness of the coating is between approximately 1 ⁇ m and approximately 20 ⁇ m.
- These cans are then purged of air, the valves crimped in place, and a suspension of about 68m g micronised beciomethasone dipropionate monohydrate in about 6.1mg water and about 18.2g P134a is filled through the valve.
- Standard 12.5 ml MDI cans Pressurepart Inc., Cary NC
- PTFE-PES blend DuPont
- the thickness of the coating is between approximately 1 ⁇ m and approximately 20 ⁇ m.
- Standard 12.5ml MDI cans Pressurepart Inc., Cary NC
- PTFE-FEP-polyamideimide blend DuPont
- the thickness of the coating is between approximately 1 ⁇ m and approximately 20 ⁇ m.
- Standard 12.5ml MDI cans Pressurepart Inc., Cary NC
- FEP powder DuPont FEP 532
- the thickness of the coating is between approximately 1 ⁇ m and approximately 20 ⁇ m.
- Standard 0.46mm thick aluminium sheet is spray coated with FEP- Benzoguanamine and cured. This sheet is then deep-drawn into cans. These cans are then purged of air, the valves crimped in place, and about 68m g micronised beciomethasone dipropionate monohydrate in about 182mg ethanol and about 18.2g P134a is filled through the valve.
- Standard 12.5 ml MDI cans Pressurepart Inc., Cary NC
- PFA Hoechst PFA-6900n
- the thickness of the coating is between approximately 1 ⁇ m and approximately 20 ⁇ m.
- These cans are then purged of air, the valves crimped in place, and about 68mg micronised beciomethasone dipropionate monohydrate in about 182mg ethanol and about 18.2g P134a is filled through the valve.
- Standard 12.5 ml MDI cans Pressurepart Inc., Cary NC
- PTFE-PES blend DuPont
- the thickness of the coating is between approximately 1 ⁇ m and approximately 20 ⁇ m.
- Standard 12.5ml MDI cans Pressurepart Inc., Cary NC
- PTFE-FEP-polyamideimide blend DuPont
- the thickness of the coating is between approximately 1 ⁇ m and approximately 20 ⁇ m.
- Standard 12.5ml MDI cans Pressurepart Inc., Cary NC
- FEP powder DuPont FEP 532
- the thickness of the coating is between approximately 1 ⁇ m and approximately 20 ⁇ m.
- Standard 0.46mm thick aluminium sheet is spray coated with FEP- Benzoguanamine and cured. This sheet is then deep-drawn into cans. These cans are then purged of air, the valves crimped in place, and about 13.6mg micronised beciomethasone dipropionate in about 107mg ethanol and about 21.4g P227 is filled through the valve.
- Standard 12.5 ml MDI cans Pressurepart Inc., Cary NC
- PFA Hoechst PFA-6900n
- the thickness of the coating is between approximately 1 ⁇ m and approximately 20 ⁇ m.
- These cans are then purged of air, the valves crimped in place, and about 13.6mg micronised beciomethasone dipropionate in about 107mg ethanol and about 21.4g P227 is filled through the valve.
- Examples 3 to 7 are repeated except that about 24m g salbutamol as the free base or equivalent weight of salt e.g. sulphate with about 12mg beciomethasone dipropionate monohydrate in about 364mg ethanol and about 18.2g P134a is filled through the valve.
- salt e.g. sulphate with about 12mg beciomethasone dipropionate monohydrate in about 364mg ethanol and about 18.2g P134a is filled through the valve.
- Examples 3 to 22 are repeated except that modified 12.5ml MDI cans having a substantially ellipsoidal base (Presspart Inc., Cary NC) are used.
- Dose delivery from the MDIs tested under simulated use conditions is found to be constant, compared to control MDIs filled into uncoated cans which exhibit a significant decrease in dose delivered through use.
Abstract
Description
Claims
Priority Applications (19)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
APAP/P/1997/001112A AP835A (en) | 1995-04-14 | 1996-04-11 | Metered dose inhaler for beclomethasone dipropionate. |
NZ306281A NZ306281A (en) | 1995-04-14 | 1996-04-11 | Metered dose inhaler with part or all internal surfaces coated with fluorocarbon polymers for dispensing beclomethasone dipropionate |
JP53118196A JP3573213B2 (en) | 1995-04-14 | 1996-04-11 | Metered dose inhaler for beclomethasone dipropionate |
AU54812/96A AU718851B2 (en) | 1995-04-14 | 1996-04-11 | Metered dose inhaler for beclomethasone dipropionate |
PL96322781A PL180880B1 (en) | 1995-04-14 | 1996-04-11 | Beclomethasone inhaler with dosis metering feature |
BR9604979A BR9604979A (en) | 1995-04-14 | 1996-04-11 | Metered dose inhaler metered dose inhaler system and use |
DE1996631476 DE69631476T2 (en) | 1995-04-14 | 1996-04-11 | DEVICE FOR DOSED INHALATION OF BECLOMETHASONE DIPROPRIONATE |
EA199700230A EA000889B1 (en) | 1995-04-14 | 1996-04-11 | Metered inhaler for beclomethasone dipropionate |
SK1391-97A SK139197A3 (en) | 1995-04-14 | 1996-04-11 | Metered dose inhaler for beclomethasone dipropionate |
US08/945,141 US6149892A (en) | 1995-04-14 | 1996-04-11 | Metered dose inhaler for beclomethasone dipropionate |
EE9700372A EE9700372A (en) | 1995-04-14 | 1996-04-11 | Beclomethasone dipropionate metered dose inhaler |
EP96911713A EP0820414B1 (en) | 1995-04-14 | 1996-04-11 | Metered dose inhaler for beclomethasone dipropionate |
AT96911713T ATE258813T1 (en) | 1995-04-14 | 1996-04-11 | DEVICE FOR THE DOSED INHALATION OF BECLOMETHASONE DIPROPRIONATE |
IS4581A IS4581A (en) | 1995-04-14 | 1997-10-07 | Inhalation device measuring specific dosage of beclomethasone dipropionate |
MXPA/A/1997/007878A MXPA97007878A (en) | 1995-04-14 | 1997-10-13 | Inhaler of measured dose for dipropionate of beclometasone |
NO974738A NO974738L (en) | 1995-04-14 | 1997-10-13 | Measured dosing device for beclomethasone dipropionate |
BG102023A BG102023A (en) | 1995-04-14 | 1997-11-05 | Metered dose inhaler for beclomethasone dipropionate |
US09/506,834 US6511652B1 (en) | 1995-04-14 | 2000-02-18 | Metered dose inhaler for beclomethasone dipropionate |
US09/506,838 US6511653B1 (en) | 1995-04-14 | 2000-02-18 | Metered dose inhaler for beclomethasone dipropionate |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US42228095A | 1995-04-14 | 1995-04-14 | |
US08/422,280 | 1995-04-14 |
Related Child Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US08/945,141 A-371-Of-International US6149892A (en) | 1995-04-14 | 1996-04-11 | Metered dose inhaler for beclomethasone dipropionate |
US09/506,838 Continuation US6511653B1 (en) | 1995-04-14 | 2000-02-18 | Metered dose inhaler for beclomethasone dipropionate |
US09/506,834 Continuation US6511652B1 (en) | 1995-04-14 | 2000-02-18 | Metered dose inhaler for beclomethasone dipropionate |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1996032345A1 true WO1996032345A1 (en) | 1996-10-17 |
Family
ID=23674168
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1996/005009 WO1996032345A1 (en) | 1995-04-14 | 1996-04-11 | Metered dose inhaler for beclomethasone dipropionate |
Country Status (26)
Country | Link |
---|---|
US (3) | US6149892A (en) |
EP (1) | EP0820414B1 (en) |
JP (1) | JP3573213B2 (en) |
KR (1) | KR19980703850A (en) |
CN (1) | CN1186473A (en) |
AP (1) | AP835A (en) |
AT (1) | ATE258813T1 (en) |
AU (1) | AU718851B2 (en) |
BG (1) | BG102023A (en) |
BR (1) | BR9604979A (en) |
CA (1) | CA2218179A1 (en) |
CZ (1) | CZ326197A3 (en) |
DE (1) | DE69631476T2 (en) |
EA (1) | EA000889B1 (en) |
EE (1) | EE9700372A (en) |
ES (1) | ES2214536T3 (en) |
GE (1) | GEP20002266B (en) |
HU (1) | HUP9800641A3 (en) |
IS (1) | IS4581A (en) |
NO (1) | NO974738L (en) |
NZ (1) | NZ306281A (en) |
OA (1) | OA10625A (en) |
PL (1) | PL180880B1 (en) |
SK (1) | SK139197A3 (en) |
TR (1) | TR199701170T1 (en) |
WO (1) | WO1996032345A1 (en) |
Cited By (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998024420A1 (en) * | 1996-12-04 | 1998-06-11 | Bioglan Ireland (R & D) Limited | Pharmaceutical compositions and devices for their administration |
WO1998041232A2 (en) * | 1997-03-18 | 1998-09-24 | Basf Aktiengesellschaft | Compositions for modulating responsiveness to corticosteroids |
WO1999042154A1 (en) * | 1998-02-23 | 1999-08-26 | Bespak Plc | Drug delivery devices |
WO1999055600A1 (en) * | 1998-04-30 | 1999-11-04 | 3M Innovative Properties Company | Metered-dose valve for pharmaceutical aerosol |
GB2338951A (en) * | 1997-09-03 | 2000-01-12 | Bespak Plc | A metering valve having a fluoropolymer lining |
US6054487A (en) * | 1997-03-18 | 2000-04-25 | Basf Aktiengesellschaft | Methods and compositions for modulating responsiveness to corticosteroids |
WO2001056639A1 (en) * | 2000-02-02 | 2001-08-09 | Pari GmbH Spezialisten für effektive Inhalation | Inhalation nebulizer |
WO2000055072A3 (en) * | 1999-03-12 | 2001-08-09 | Glaxo Group Ltd | Aerosol metering valve |
WO2001064273A2 (en) * | 2000-03-01 | 2001-09-07 | Glaxo Group Limited | Metered dose inhaler |
WO2001064275A1 (en) * | 2000-03-01 | 2001-09-07 | Glaxo Group Limited | Metered dose inhaler |
US6315985B1 (en) | 1999-06-18 | 2001-11-13 | 3M Innovative Properties Company | C-17/21 OH 20-ketosteroid solution aerosol products with enhanced chemical stability |
WO2001087392A2 (en) | 2000-05-15 | 2001-11-22 | Glaxo Group Limited | Method and package for storing a pressurized container containing a drug |
JP2001526685A (en) * | 1997-05-21 | 2001-12-18 | ミネソタ マイニング アンド マニュファクチャリング カンパニー | Medicated aerosol products |
WO2001098176A2 (en) | 2000-06-22 | 2001-12-27 | Glaxo Group Limited | Package for a pressurized container containing a drug |
WO2001098175A1 (en) | 2000-06-20 | 2001-12-27 | Glaxo Group Limited | Method and package for storing a pressurized container containing a drug |
WO2001097888A2 (en) | 2000-06-22 | 2001-12-27 | Glaxo Group Limited | Method and package for storing a pressurized container containing a drug |
WO2002024552A2 (en) | 2000-09-18 | 2002-03-28 | Glaxo Group Limited | Coated can for a metered dose inhaler |
WO2001064524A3 (en) * | 2000-03-01 | 2002-03-28 | Glaxo Group Ltd | Metered dose inhaler |
WO2002047829A1 (en) | 2000-12-13 | 2002-06-20 | Astrazeneca Ab | Surface modification process |
US6413496B1 (en) | 1996-12-04 | 2002-07-02 | Biogland Ireland (R&D) Limited | Pharmaceutical compositions and devices for their administration |
WO2002051483A1 (en) | 2000-12-22 | 2002-07-04 | Glaxo Group Limited | Metered dose inhaler for salmeterol xinafoate |
AU753921B2 (en) * | 1998-02-23 | 2002-10-31 | Glaxo Group Limited | Improvements in drug delivery devices |
JP2003534063A (en) * | 2000-05-23 | 2003-11-18 | グラクソ グループ リミテッド | Aerosol container for salmeterol xinafoate formulation |
JP2004502719A (en) * | 2000-07-11 | 2004-01-29 | アストラゼネカ・アクチエボラーグ | Novel aerosol formulation containing polar fluorinated molecules |
WO2005000712A1 (en) * | 2003-06-24 | 2005-01-06 | Cipla Limited | Pharmaceutical dispensing aid |
US6866039B1 (en) | 2000-10-12 | 2005-03-15 | Bespak Plc | Dispensing apparatus |
WO2005023330A2 (en) | 2003-08-29 | 2005-03-17 | Glaxo Group Limited | Pharmaceutical metered dose inhaler and methods relating thereto |
EP1523975A3 (en) * | 1998-11-25 | 2005-08-31 | CHIESI FARMACEUTICI S.p.A. | Pressurised metered dose inhalers (MDI) |
US6945953B2 (en) | 2002-01-22 | 2005-09-20 | Bespak Plc | Dispensing apparatus for delivering powdered product |
US6964759B2 (en) | 2000-02-22 | 2005-11-15 | Chiesi Farmaceutici S.P.A. | Formulations containing an anticholinergic drug for the treatment of chronic obstructive pulmonary disease |
US6967017B1 (en) | 1999-07-23 | 2005-11-22 | Chiesi Farmaceutici S.P.A. | Formulations of steroid solutions for inhalatory administration |
US7018618B2 (en) | 2000-05-22 | 2006-03-28 | Chiesi Farmaceutici S.P.A. | Stable pharmaceutical solution formulations for pressurized metered dose inhalers |
US7086571B2 (en) | 2001-04-30 | 2006-08-08 | Bespak Plc | Valves for pressurized dispensing containers |
US7381402B2 (en) | 2004-02-27 | 2008-06-03 | Chiesi Farmaceutici S.P.A. | Stable pharmaceutical solution formulations for pressurized metered dose inhalers |
GB2456028A (en) * | 2008-11-14 | 2009-07-01 | Consort Medical Plc | A medicament dispenser with an HFO propellant |
US7566445B1 (en) | 1996-08-01 | 2009-07-28 | Norton Healthcare Limited | Medicinal aerosols and methods of delivery thereof |
US7696178B2 (en) | 2001-07-02 | 2010-04-13 | Chiesi Farmaceutici S.P.A. | Optimised formulation of tobramycin for aerosolization |
WO2010129758A1 (en) | 2009-05-06 | 2010-11-11 | 3M Innovative Properties Company | Medicinal inhalation devices and components thereof |
US7845346B2 (en) * | 2000-08-18 | 2010-12-07 | Norton Healthcare Ltd. | Spray device |
EP2275479A1 (en) | 2003-08-11 | 2011-01-19 | Glaxo Group Limited | Pharmaceutical metered dose inhaler and methods relating thereto |
WO2011061498A2 (en) | 2009-11-17 | 2011-05-26 | Cipla Limited | Inhalation solutions |
US8104469B2 (en) | 2007-11-06 | 2012-01-31 | 3M Innovative Properties Company | Medicinal inhalation devices and components thereof |
US8414956B2 (en) | 2007-11-06 | 2013-04-09 | 3M Innovative Properties Company | Medicinal inhalation devices and components thereof |
US8420058B2 (en) | 1997-06-13 | 2013-04-16 | Chiesi Farmaceutici S.P.A. | Pharmaceutical aerosol composition |
US8616201B2 (en) | 2007-11-06 | 2013-12-31 | 3M Innovative Properties Company | Medicinal inhalation devices and components thereof |
US8815325B2 (en) | 2009-05-06 | 2014-08-26 | 3M Innovative Properties Company | Medicinal inhalation device |
US10266455B2 (en) | 2007-12-07 | 2019-04-23 | The Sherwin-Williams Company | Coating suitable for medicament contact |
US10410838B2 (en) | 2009-05-06 | 2019-09-10 | 3M Innovative Properties Company | Apparatus and method for plasma treatment of containers |
GB2593970A (en) * | 2020-02-20 | 2021-10-13 | Chiesi Farm Spa | Pressurised metered dose inhalers comprising a buffered pharmaceutical formulation |
Families Citing this family (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4003270A1 (en) * | 1990-02-03 | 1991-08-08 | Boehringer Ingelheim Kg | NEW SPEED GASES AND THEIR USE IN MEDICINE PREPARATIONS |
EE04004B1 (en) * | 1995-04-14 | 2003-04-15 | Glaxo Wellcome Inc. | Fluticasone propionate metered dose inhaler |
HUP9800641A3 (en) * | 1995-04-14 | 2001-04-28 | Glaxo Wellcome Inc Res Triangl | Metered dose inhaler for beclomethasone dipropionate |
MX9707864A (en) * | 1995-04-14 | 1997-11-29 | Glaxo Wellcome Inc | Metered dose inhaler for salmeterol. |
GB9526392D0 (en) | 1995-12-22 | 1996-02-21 | Glaxo Group Ltd | Medicaments |
US20030103906A1 (en) * | 1997-10-14 | 2003-06-05 | Smithkline Beecham Corporation | Metered dose inhaler having internal surfaces coated with fluorocarbon polymer |
GB9814717D0 (en) * | 1998-02-23 | 1998-09-02 | Bespak Plc | Improvements in drug delivery devices |
GB9805938D0 (en) * | 1998-03-19 | 1998-05-13 | Glaxo Group Ltd | Valve for aerosol container |
GB2340759B (en) * | 1998-08-26 | 2003-05-07 | Bespak Plc | Improvements in drug delivery devices |
IT1317720B1 (en) * | 2000-01-07 | 2003-07-15 | Chiesi Farma Spa | DEVICE FOR THE ADMINISTRATION OF AEROSOL DOSED PRESSURIZED INPROPELLENT HYDROFLUOROALKANS. |
NZ521034A (en) | 2000-02-28 | 2004-08-27 | Vectura Ltd | Improvements in or relating to the delivery of oral drugs |
JP2003525090A (en) * | 2000-03-01 | 2003-08-26 | グラクソ グループ リミテッド | Metered dose inhaler |
IT1318514B1 (en) * | 2000-05-12 | 2003-08-27 | Chiesi Farma Spa | FORMULATIONS CONTAINING A GLUCOCORTICOSTEROID DRUG FOR THE TREATMENT OF BRONCOPOLMONARY DISEASES. |
US7458374B2 (en) | 2002-05-13 | 2008-12-02 | Alexza Pharmaceuticals, Inc. | Method and apparatus for vaporizing a compound |
US20070122353A1 (en) | 2001-05-24 | 2007-05-31 | Hale Ron L | Drug condensation aerosols and kits |
US7766013B2 (en) | 2001-06-05 | 2010-08-03 | Alexza Pharmaceuticals, Inc. | Aerosol generating method and device |
US7645442B2 (en) | 2001-05-24 | 2010-01-12 | Alexza Pharmaceuticals, Inc. | Rapid-heating drug delivery article and method of use |
GB0122725D0 (en) * | 2001-09-21 | 2001-11-14 | Glaxo Group Ltd | Drug dispensing components |
SE0200313D0 (en) * | 2002-02-01 | 2002-02-01 | Astrazeneca Ab | Novel process |
US20040126325A1 (en) * | 2002-03-12 | 2004-07-01 | David Lewis | Medicinal aerosol solution formulation products with improved chemical stability |
AU2003270602A1 (en) * | 2002-09-13 | 2004-04-30 | Glaxo Group Limited | Coated blending system |
US20040105818A1 (en) | 2002-11-26 | 2004-06-03 | Alexza Molecular Delivery Corporation | Diuretic aerosols and methods of making and using them |
US7913688B2 (en) | 2002-11-27 | 2011-03-29 | Alexza Pharmaceuticals, Inc. | Inhalation device for producing a drug aerosol |
US20060076010A1 (en) * | 2002-12-18 | 2006-04-13 | King Michael L | Drug delivery system with vented mouthpiece |
PT1608336E (en) * | 2003-03-20 | 2008-04-21 | Boehringer Ingelheim Pharma | Formulation for a metered dose inhaler using hydro-fluoro-alkanes as propellants |
US20040191176A1 (en) * | 2003-03-28 | 2004-09-30 | Kaplan Leonard W | Formulations for treatment of pulmonary disorders |
CA2543482A1 (en) * | 2003-10-28 | 2005-05-19 | Glaxo Group Limited | Inhalable pharmaceutical formulations employing lactose anhydrate and methods of administering the same |
FR2872494B1 (en) * | 2004-07-01 | 2006-11-17 | Valois Sas | DISPENSER OF FLUID OR PULVERIZING PRODUCTS |
EA013428B1 (en) * | 2004-07-02 | 2010-04-30 | Бёрингер Ингельхайм Интернациональ Гмбх | Aerosol suspension formulations containing tg 227 ea or tg 134 a as a propellant |
RU2007133547A (en) * | 2005-02-10 | 2009-03-20 | Глаксо Груп Лимитед (GB) | METHODS FOR PRODUCING LACTOSES USING PRELIMINARY SORTING METHODS AND PHARMACEUTICAL COMPOSITIONS PRODUCED FROM IT |
WO2006086130A2 (en) * | 2005-02-10 | 2006-08-17 | Glaxo Group Limited | Process for crystallizing lactose particles for use in pharmaceutical formulations |
DE102006017320A1 (en) * | 2006-04-11 | 2007-10-18 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Aerosol suspension formulations with TG 227 ea or TG 134 a as propellant |
ES2538082T3 (en) * | 2007-02-11 | 2015-06-17 | Map Pharmaceuticals Inc | Therapeutic administration method of DHE to allow rapid migraine relief while minimizing the side effects profile |
US20080216828A1 (en) | 2007-03-09 | 2008-09-11 | Alexza Pharmaceuticals, Inc. | Heating unit for use in a drug delivery device |
EP2647372A1 (en) | 2008-09-04 | 2013-10-09 | Maria Clementine Martin Klosterfrau Vertriebsgesellschaft mbH | Monoterpenes for treating respiratory tract diseases, in particular bronchopulmonary diseases |
US10231948B2 (en) | 2017-02-27 | 2019-03-19 | Jason Ty Nguyen | Metered dose inhaler compositions, systems, and methods |
WO2019025994A2 (en) * | 2017-08-03 | 2019-02-07 | 3M Innovative Properties Company | Coating process |
GB201717996D0 (en) | 2017-10-31 | 2017-12-13 | Portal Medical Ltd | Medicament dispenser device |
CN110840864B (en) * | 2019-12-20 | 2022-02-22 | 广州健康元呼吸药物工程技术有限公司 | Beta 2 receptor agonist inhalation aerosol and product containing same |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1981001375A1 (en) * | 1979-11-22 | 1981-05-28 | Glyco Metall Werke | Composite material with two or a plurality of layers |
WO1992008446A1 (en) * | 1990-11-09 | 1992-05-29 | Glaxo Group Limited | Aerosol medicaments |
US5176132A (en) * | 1989-05-31 | 1993-01-05 | Fisons Plc | Medicament inhalation device and formulation |
US5202110A (en) * | 1992-01-22 | 1993-04-13 | Virginia Commonwealth University | Formulations for delivery of beclomethasone diproprionate by metered dose inhalers containing no chlorofluorocarbon propellants |
WO1993011743A1 (en) * | 1991-12-12 | 1993-06-24 | Glaxo Group Limited | Medicaments |
WO1994003153A1 (en) * | 1992-07-31 | 1994-02-17 | Glaxo Group Limited | Surfactant free aerosol formulations containing beclomethasone dipropionate |
EP0642992A2 (en) * | 1993-08-27 | 1995-03-15 | Ciba-Geigy Ag | Metered aerosol with CFC free propellant and dosing valve as well as application thereof |
Family Cites Families (104)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AT12188B (en) | 1901-04-18 | 1903-06-10 | William Chapman | |
US2562118A (en) * | 1950-02-09 | 1951-07-24 | Du Pont | Polytetrafluoroethylene coating compositions |
BE549064A (en) * | 1954-09-20 | |||
US2968427A (en) * | 1955-06-28 | 1961-01-17 | Meshberg Philip | Valve for aerosol container |
GB878409A (en) * | 1957-03-26 | 1961-09-27 | United Drug And Chemical Compa | Improvements in or relating to dispensing devices |
US2886217A (en) * | 1957-05-20 | 1959-05-12 | Riker Laboratories Inc | Dispensing device |
US2892576A (en) * | 1957-11-14 | 1959-06-30 | Lawrence T Ward | Metering button valve assembly |
US2980301A (en) * | 1958-09-02 | 1961-04-18 | Riker Laboratories Inc | Metering valve for aerosol container |
GB864392A (en) * | 1958-11-10 | 1961-04-06 | Rexall Drug Company Ltd | Improvements in or relating to dispensing devices for aerosols |
US3506737A (en) | 1965-10-23 | 1970-04-14 | Owens Illinois Inc | Glass aerosol bottles and method for making same |
GB1191700A (en) | 1967-02-27 | 1970-05-13 | Ekco Prod Inc | Coated Metalware |
US3505737A (en) * | 1967-10-02 | 1970-04-14 | Theodore L Merolla | Fluid substitution device |
FR1584784A (en) * | 1968-08-13 | 1970-01-02 | ||
FR2082593A5 (en) | 1970-03-20 | 1971-12-10 | Oreal | Aerosol can prodn |
NO134730L (en) | 1971-07-19 | 1900-01-01 | ||
LU63737A1 (en) | 1971-08-17 | 1972-01-04 | ||
US4087026A (en) * | 1971-09-15 | 1978-05-02 | Petterson Tor H | Barrier package |
US3896602A (en) * | 1971-09-15 | 1975-07-29 | Tor H Petterson | Method of manufacturing of a barrier package |
FR2159593A5 (en) * | 1971-11-04 | 1973-06-22 | Skm Sa | Paint spraying unit - with paint reservoir and supply channels coated in ptfe to prevent sticking |
US4143204A (en) * | 1971-12-27 | 1979-03-06 | E. I. Du Pont De Nemours And Company | Articles coated with fluorocarbon resins |
DE2227142A1 (en) * | 1972-06-03 | 1973-12-13 | Pampus Kg | PIPES AND TANK MADE FROM GLASS FIBER REINFORCED PLASTIC AND A LINING, FOR EXAMPLE MADE OF PTFE |
US3962171A (en) * | 1973-03-02 | 1976-06-08 | Mcgarry & Waters | Composition for protecting surfaces |
US3929537A (en) * | 1973-07-19 | 1975-12-30 | Austral Erwin Engineering Co | Preparation of plastic-metal laminates |
FR2267496A1 (en) * | 1974-04-11 | 1975-11-07 | Sidel Sa | Method of sealing valve on aerosol container - uses internally ribbed sleeve over ribbed valve and sleeve |
US4180609A (en) * | 1975-07-11 | 1979-12-25 | E. I. Du Pont De Nemours And Company | Article coated with fluoropolymer finish with improved scratch resistance |
JPS5327120A (en) | 1976-08-26 | 1978-03-14 | Union Carbide Corp | Plasticssmade aerosol containers and method of producing the same |
GB2003415A (en) | 1977-09-02 | 1979-03-14 | American Can Co | Improvements relating to the manufacture of containers |
US4125152A (en) * | 1977-09-19 | 1978-11-14 | Borg-Warner Corporation | Scale resistant heat transfer surfaces and a method for their preparation |
JPS5920547B2 (en) * | 1979-07-04 | 1984-05-14 | 東洋製罐株式会社 | welding can |
ZA807387B (en) * | 1979-12-08 | 1981-11-25 | Metal Box Co Ltd | Containers |
CA1201114A (en) * | 1980-02-15 | 1986-02-25 | Gordon H. Phillipps | Androstane carbothioates |
GB2077229B (en) * | 1980-05-16 | 1983-08-03 | Neotechnic Eng Ltd | Valve assembly for a pressurized aerosoldispensing container |
GB2105189B (en) | 1981-07-24 | 1985-03-20 | Fisons Plc | Inhalation drugs |
ZW6584A1 (en) * | 1983-04-18 | 1985-04-17 | Glaxo Group Ltd | Phenethanolamine derivatives |
US4487878A (en) * | 1983-06-30 | 1984-12-11 | E. I. Du Pont De Nemours And Company | Coating composition of a solution fluorocarbon polymer, a dispersed fluorocarbon polymer and a polyamine curing agent |
DE3677811D1 (en) * | 1985-04-19 | 1991-04-11 | Nippon Steel Corp | RIFLE AND METHOD FOR PRODUCING RIFLES. |
NL8501767A (en) * | 1985-06-19 | 1987-01-16 | Euro Technical Oilservices Bv | DEVICE FOR TREATING A POLLUTION-CONTAINING LIQUID. |
EP0234774B1 (en) * | 1986-02-27 | 1992-05-06 | Nippon Kokan Kabushiki Kaisha | Precoating metal sheet |
JPS6312445A (en) * | 1986-06-24 | 1988-01-19 | 東洋製罐株式会社 | Can body with easy-open cover and manufacture thereof |
US5536583A (en) * | 1986-07-01 | 1996-07-16 | Edlon Products, Inc. | Polymer metal bonded composite and method of producing same |
US4897439A (en) * | 1986-07-01 | 1990-01-30 | Edlon Products, Inc. | Polymer-metal bonded composite and method of producing same |
EP0260084B1 (en) * | 1986-09-08 | 1992-12-30 | Asia Can Company Limited | Metal container and method of manufacturing the same |
US4819834A (en) * | 1986-09-09 | 1989-04-11 | Minnesota Mining And Manufacturing Company | Apparatus and methods for delivering a predetermined amount of a pressurized fluid |
GB2205297B (en) * | 1987-06-05 | 1991-06-19 | Lin Pac Mouldings | A container assembly |
DE3886184D1 (en) * | 1987-06-26 | 1994-01-20 | Werding Winfried J | DEVICE FOR STORING AND CONTROLLED DELIVERY OF PRODUCTS UNDER PRESSURE AND METHOD FOR THE PRODUCTION THEREOF. |
DE8709978U1 (en) * | 1987-07-21 | 1987-10-08 | A. U. K. Mueller Gmbh & Co Kg, 4000 Duesseldorf, De | |
GB8724242D0 (en) * | 1987-10-15 | 1987-11-18 | Metal Box Plc | Laminated metal sheet |
GB8724243D0 (en) * | 1987-10-15 | 1987-11-18 | Metal Box Plc | Laminates of polyolefin-based film |
IT1223451B (en) * | 1987-11-24 | 1990-09-19 | Coster Tecnologie Speciali Spa | PROCEDURE FOR OBTAINING METALLIC BOTTLES PROTECTED FOR VALVES FOR AEROSOL AND SIMILAR |
GB2214891A (en) | 1988-02-05 | 1989-09-13 | Fibrenyle Ltd | Containers for pressurized material |
DE68915203T2 (en) | 1988-03-22 | 1994-09-22 | Fisons Plc | Pharmaceutical blends. |
FI94342C (en) * | 1988-03-29 | 1995-08-25 | Ciba Geigy Ag | Process for the preparation of new alkanophenones |
JPH0289633A (en) | 1988-05-20 | 1990-03-29 | Sumitomo Electric Ind Ltd | Fluororesin covered matter |
US4961966A (en) * | 1988-05-25 | 1990-10-09 | The United States Of America As Represented By The Administrator Of The Environmental Protection Agency | Fluorocarbon coating method |
US4902318A (en) * | 1988-05-25 | 1990-02-20 | The United States Of America As Represented By The Administrator Of The Environmental Protection Agency | Inlet apparatus for gas-aerosol sampling |
US5225183A (en) * | 1988-12-06 | 1993-07-06 | Riker Laboratories, Inc. | Medicinal aerosol formulations |
GB8828477D0 (en) * | 1988-12-06 | 1989-01-05 | Riker Laboratories Inc | Medical aerosol formulations |
GB8903629D0 (en) * | 1989-02-17 | 1989-04-05 | Metal Box Plc | Metal/polymer laminates |
US5006383A (en) * | 1989-06-28 | 1991-04-09 | The Dow Chemical Company | Polymeric blend and laminated structures prepared therefrom |
FR2649359B1 (en) * | 1989-07-06 | 1993-02-12 | Cebal | STRIP OR PORTION OF STRIP FOR STAMPING OR STAMPING, AND ITS USE |
FR2650219B1 (en) * | 1989-07-06 | 1991-10-04 | Pechiney Rhenalu | PROCESS FOR OBTAINING MULTI-LAYERED MATERIALS SUITABLE FOR TRANSFORMATION BY STAMPING OR STAMPING IN HOLLOW BODY |
US4972037A (en) * | 1989-08-07 | 1990-11-20 | Minnesota Mining And Manufacturing Company | Polysiloxane-grafted copolymer topical binder composition with novel fluorochemical comonomer and method of coating therewith |
US5208226A (en) * | 1989-09-08 | 1993-05-04 | Glaxo Group Limited | Medicaments |
US5270305A (en) * | 1989-09-08 | 1993-12-14 | Glaxo Group Limited | Medicaments |
US5345980A (en) * | 1989-09-21 | 1994-09-13 | Glaxo Group Limited | Method and apparatus an aerosol container |
US5043191A (en) * | 1990-02-27 | 1991-08-27 | Miles Inc. | Method of protecting hard surfaces |
DE4009397A1 (en) * | 1990-03-23 | 1991-09-26 | Weidenhammer Packungen | CAN-LIKE PACKAGING FOR FLOWABLE PRODUCTS |
US5192548A (en) * | 1990-04-30 | 1993-03-09 | Riker Laboratoires, Inc. | Device |
AU614234B1 (en) * | 1990-06-28 | 1991-08-22 | Kabushiki Gaisha Tokai | Vessel for aerosol |
DE4023909A1 (en) * | 1990-07-27 | 1992-01-30 | Wild Rudolf Gmbh & Co | REUSABLE PLASTIC CONTAINER AND ITS PRODUCTION AND USE |
DE69132258D1 (en) * | 1990-11-14 | 2000-07-27 | Titeflex Corp | Laminates made of fluoropolymer and aluminum |
AU652017B2 (en) * | 1990-12-12 | 1994-08-11 | E.I. Du Pont De Nemours And Company | Non-stick coating system with PTFE of different melt viscosities for concentration gradient |
JPH07108385B2 (en) * | 1990-12-12 | 1995-11-22 | イー・アイ・デユポン・ドウ・ヌムール・アンド・カンパニー | Non-stick coating system with PTFE and PFA or FEP for concentration gradient |
US5168107A (en) * | 1990-12-12 | 1992-12-01 | E. I. Du Pont De Nemours And Company | Non-stick coating system with PTFE of two low melt viscosities for concentration gradient |
GB9027234D0 (en) * | 1990-12-15 | 1991-02-06 | Harris Pharma Ltd | An inhalation device |
EP0499142A3 (en) * | 1991-02-09 | 1993-05-05 | Hoechst Aktiengesellschaft | Potentiation of the antireactive-antiasthmatic effect of inhaled loop diuretics by inhaled non steroidal anti-flammatory drugs |
EP0504112A3 (en) * | 1991-03-14 | 1993-04-21 | Ciba-Geigy Ag | Pharmaceutical aerosol formulations |
RU2027448C1 (en) | 1991-04-25 | 1995-01-27 | Государственное предприятие "ВЭЛТ" | Inhaler |
RU2008939C1 (en) | 1991-06-10 | 1994-03-15 | Вячеслав Николаевич Поздняков | Physiotherapeutic inhalator |
RU2012362C1 (en) | 1991-06-24 | 1994-05-15 | Юрий Алексеевич Волгин | Inhaler |
DE4124730C3 (en) * | 1991-07-25 | 2001-09-06 | Ahc Oberflaechentechnik Gmbh | Anodized objects made of aluminum or magnesium with fluoropolymers embedded in the oxide layer and process for their production |
US5653962A (en) * | 1991-12-12 | 1997-08-05 | Glaxo Group Limited | Aerosol formulations containing P134a and particulate medicaments |
US5736124A (en) * | 1991-12-12 | 1998-04-07 | Glaxo Group Limited | Aerosol formulations containing P134a and particulate medicament |
US5261538A (en) * | 1992-04-21 | 1993-11-16 | Glaxo Inc. | Aerosol testing method |
US5525991A (en) * | 1992-06-25 | 1996-06-11 | Nippondenso Co., Ltd. | Mobile object identification system |
US5376359A (en) * | 1992-07-07 | 1994-12-27 | Glaxo, Inc. | Method of stabilizing aerosol formulations |
US5250356A (en) * | 1992-08-28 | 1993-10-05 | E. I. Du Pont De Nemours And Company | Cookware coating system |
IT1263783B (en) * | 1993-01-21 | 1996-08-29 | Claudio Bignami | FORMULATIONS OF VARNISHING PRODUCTS FOR NON-STICK COATINGS, APPLICABLE BY ROLLING WITH NON-PICKLED ALUMINUM DISCS USABLE FOR THE MOLDING OF DOMESTIC PANS |
US5411771A (en) * | 1993-04-29 | 1995-05-02 | Tsai; Tung-Hung | Method for coating metal cookware |
JP3093525B2 (en) | 1993-07-02 | 2000-10-03 | 九州日本電気株式会社 | Semiconductor integrated circuit |
US5421492A (en) * | 1993-11-02 | 1995-06-06 | Glaxo Inc. | Metered aerosol dispensing apparatus and method of use thereof |
FR2713299B1 (en) * | 1993-12-01 | 1996-02-16 | Joint Francais | Sealed piston and aerosol comprising such a piston. |
US5468798A (en) * | 1994-02-18 | 1995-11-21 | Whitford Corporation | Basecoat for a coating system |
US5447600A (en) * | 1994-03-21 | 1995-09-05 | Texas Instruments | Polymeric coatings for micromechanical devices |
US5508023A (en) * | 1994-04-11 | 1996-04-16 | The Center For Innovative Technology | Pharmaceutically acceptable agents for solubilizing, wetting, emulsifying, or lubricating in metered dose inhaler formulations which use HFC-227 propellant |
US5597433A (en) * | 1994-05-27 | 1997-01-28 | Panoramic, Inc. | Method and apparatus for manufacturing plastic canisters |
DE4434425C2 (en) * | 1994-09-27 | 1997-04-03 | Fissler Gmbh | Process for producing a non-stick coating and articles provided with such |
DE19500726C2 (en) * | 1995-01-12 | 1998-07-02 | Fraunhofer Ges Forschung | Device for dosing the smallest amounts of powder to produce an aerosol |
HUP9800641A3 (en) * | 1995-04-14 | 2001-04-28 | Glaxo Wellcome Inc Res Triangl | Metered dose inhaler for beclomethasone dipropionate |
EE04004B1 (en) * | 1995-04-14 | 2003-04-15 | Glaxo Wellcome Inc. | Fluticasone propionate metered dose inhaler |
MX9707864A (en) * | 1995-04-14 | 1997-11-29 | Glaxo Wellcome Inc | Metered dose inhaler for salmeterol. |
CA2217950C (en) * | 1995-04-14 | 2001-12-25 | Glaxo Wellcome Inc. | Metered dose inhaler for albuterol |
US5674592A (en) * | 1995-05-04 | 1997-10-07 | Minnesota Mining And Manufacturing Company | Functionalized nanostructured films |
US5891420A (en) * | 1997-04-21 | 1999-04-06 | Aeropharm Technology Limited | Environmentally safe triancinolone acetonide aerosol formulations for oral inhalation |
-
1996
- 1996-04-11 HU HU9800641A patent/HUP9800641A3/en unknown
- 1996-04-11 AT AT96911713T patent/ATE258813T1/en not_active IP Right Cessation
- 1996-04-11 EE EE9700372A patent/EE9700372A/en unknown
- 1996-04-11 KR KR1019970707250A patent/KR19980703850A/en not_active Application Discontinuation
- 1996-04-11 SK SK1391-97A patent/SK139197A3/en unknown
- 1996-04-11 CN CN96194409A patent/CN1186473A/en active Pending
- 1996-04-11 NZ NZ306281A patent/NZ306281A/en unknown
- 1996-04-11 BR BR9604979A patent/BR9604979A/en not_active Application Discontinuation
- 1996-04-11 US US08/945,141 patent/US6149892A/en not_active Expired - Fee Related
- 1996-04-11 JP JP53118196A patent/JP3573213B2/en not_active Expired - Fee Related
- 1996-04-11 PL PL96322781A patent/PL180880B1/en unknown
- 1996-04-11 AU AU54812/96A patent/AU718851B2/en not_active Ceased
- 1996-04-11 CA CA002218179A patent/CA2218179A1/en not_active Abandoned
- 1996-04-11 CZ CZ973261A patent/CZ326197A3/en unknown
- 1996-04-11 EP EP96911713A patent/EP0820414B1/en not_active Revoked
- 1996-04-11 TR TR97/01170T patent/TR199701170T1/en unknown
- 1996-04-11 EA EA199700230A patent/EA000889B1/en not_active IP Right Cessation
- 1996-04-11 GE GEAP19963926A patent/GEP20002266B/en unknown
- 1996-04-11 WO PCT/US1996/005009 patent/WO1996032345A1/en not_active Application Discontinuation
- 1996-04-11 AP APAP/P/1997/001112A patent/AP835A/en active
- 1996-04-11 ES ES96911713T patent/ES2214536T3/en not_active Expired - Lifetime
- 1996-04-11 DE DE1996631476 patent/DE69631476T2/en not_active Revoked
-
1997
- 1997-10-07 IS IS4581A patent/IS4581A/en unknown
- 1997-10-10 OA OA70103A patent/OA10625A/en unknown
- 1997-10-13 NO NO974738A patent/NO974738L/en not_active Application Discontinuation
- 1997-11-05 BG BG102023A patent/BG102023A/en unknown
-
2000
- 2000-02-18 US US09/506,834 patent/US6511652B1/en not_active Expired - Fee Related
- 2000-02-18 US US09/506,838 patent/US6511653B1/en not_active Expired - Fee Related
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1981001375A1 (en) * | 1979-11-22 | 1981-05-28 | Glyco Metall Werke | Composite material with two or a plurality of layers |
US5176132A (en) * | 1989-05-31 | 1993-01-05 | Fisons Plc | Medicament inhalation device and formulation |
WO1992008446A1 (en) * | 1990-11-09 | 1992-05-29 | Glaxo Group Limited | Aerosol medicaments |
WO1993011743A1 (en) * | 1991-12-12 | 1993-06-24 | Glaxo Group Limited | Medicaments |
US5202110A (en) * | 1992-01-22 | 1993-04-13 | Virginia Commonwealth University | Formulations for delivery of beclomethasone diproprionate by metered dose inhalers containing no chlorofluorocarbon propellants |
WO1994003153A1 (en) * | 1992-07-31 | 1994-02-17 | Glaxo Group Limited | Surfactant free aerosol formulations containing beclomethasone dipropionate |
EP0642992A2 (en) * | 1993-08-27 | 1995-03-15 | Ciba-Geigy Ag | Metered aerosol with CFC free propellant and dosing valve as well as application thereof |
Cited By (82)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8834849B2 (en) | 1996-08-01 | 2014-09-16 | Norton Healthcare Limited | Medicinal aerosols and methods of delivery thereof |
US7566445B1 (en) | 1996-08-01 | 2009-07-28 | Norton Healthcare Limited | Medicinal aerosols and methods of delivery thereof |
US9650203B2 (en) | 1996-08-01 | 2017-05-16 | Norton Healthcare Limited | Medicinal aerosols and methods of delivery thereof |
WO1998024420A1 (en) * | 1996-12-04 | 1998-06-11 | Bioglan Ireland (R & D) Limited | Pharmaceutical compositions and devices for their administration |
US6413496B1 (en) | 1996-12-04 | 2002-07-02 | Biogland Ireland (R&D) Limited | Pharmaceutical compositions and devices for their administration |
AU726510B2 (en) * | 1996-12-04 | 2000-11-09 | Consort Medical Plc | Pharmaceutical compositions and devices for their administration |
WO1998041232A2 (en) * | 1997-03-18 | 1998-09-24 | Basf Aktiengesellschaft | Compositions for modulating responsiveness to corticosteroids |
US6054487A (en) * | 1997-03-18 | 2000-04-25 | Basf Aktiengesellschaft | Methods and compositions for modulating responsiveness to corticosteroids |
WO1998041232A3 (en) * | 1997-03-18 | 2000-10-05 | Basf Ag | Compositions for modulating responsiveness to corticosteroids |
AU734756B2 (en) * | 1997-03-18 | 2001-06-21 | Basf Aktiengesellschaft | Compositions for modulating responsiveness to corticosteroids |
JP2001526685A (en) * | 1997-05-21 | 2001-12-18 | ミネソタ マイニング アンド マニュファクチャリング カンパニー | Medicated aerosol products |
US8420058B2 (en) | 1997-06-13 | 2013-04-16 | Chiesi Farmaceutici S.P.A. | Pharmaceutical aerosol composition |
GB2338951B (en) * | 1997-09-03 | 2000-06-21 | Bespak Plc | Improvements in or relating to metering valves for pressuriseddispensing containers |
GB2338951A (en) * | 1997-09-03 | 2000-01-12 | Bespak Plc | A metering valve having a fluoropolymer lining |
HRP20000548B1 (en) * | 1998-02-23 | 2009-04-30 | Glaxo Group Limited | Drug delivery devices |
EP1208864A2 (en) * | 1998-02-23 | 2002-05-29 | Glaxo Group Limited | Improvements in drug delivery devices |
EP1208864A3 (en) * | 1998-02-23 | 2003-12-17 | Glaxo Group Limited | Improvements in drug delivery devices |
EP1088567A3 (en) * | 1998-02-23 | 2003-12-17 | Bespak plc | Improvements in drug delivery devices |
AU742080B2 (en) * | 1998-02-23 | 2001-12-20 | Bespak Plc | Drug delivery devices |
WO1999042154A1 (en) * | 1998-02-23 | 1999-08-26 | Bespak Plc | Drug delivery devices |
CZ299696B6 (en) * | 1998-02-23 | 2008-10-22 | Glaxo Group Limited | Metering valve for use with pressurized dispensing container |
EP1088567A2 (en) * | 1998-02-23 | 2001-04-04 | Bespak plc | Improvements in drug delivery devices |
AU753921B2 (en) * | 1998-02-23 | 2002-10-31 | Glaxo Group Limited | Improvements in drug delivery devices |
JP2009136695A (en) * | 1998-02-23 | 2009-06-25 | Glaxo Group Ltd | Drug delivery device |
WO1999055600A1 (en) * | 1998-04-30 | 1999-11-04 | 3M Innovative Properties Company | Metered-dose valve for pharmaceutical aerosol |
US7223381B2 (en) | 1998-11-25 | 2007-05-29 | Chiesi Farmaceutici S.P.A. | Pressurised metered dose inhalers (MDI) |
EP1674079A3 (en) * | 1998-11-25 | 2006-07-05 | CHIESI FARMACEUTICI S.p.A. | Pressurised metered dose inhalers (MDI) |
EP1674079A2 (en) | 1998-11-25 | 2006-06-28 | CHIESI FARMACEUTICI S.p.A. | Pressurised metered dose inhalers (MDI) |
US7347199B1 (en) | 1998-11-25 | 2008-03-25 | Chiesi Farmaceutici S.P.A. | Pressurised metered dose inhalers (MDI) |
EP1666029A1 (en) * | 1998-11-25 | 2006-06-07 | CHIESI FARMACEUTICI S.p.A. | Pressurised metered dose inhalers (MDI) |
EP1523975A3 (en) * | 1998-11-25 | 2005-08-31 | CHIESI FARMACEUTICI S.p.A. | Pressurised metered dose inhalers (MDI) |
BG65596B1 (en) * | 1998-11-25 | 2009-02-27 | Chiesi Farmaceutici S.P.A. | Pressurised metered dose inhaler (mdi) |
US8142763B2 (en) | 1998-11-25 | 2012-03-27 | Chiesi Farmaceutici S.P.A. | Pressurized metered dose inhalers (MDI) containing a solution comprising ipratropium bromide, HFA propellant, and co-solvent and comprising a container with a specific internal surface composition and/or lining |
US7168597B1 (en) | 1999-03-12 | 2007-01-30 | Smithkline Beecham Corporation | Aerosol metering valve |
WO2000055072A3 (en) * | 1999-03-12 | 2001-08-09 | Glaxo Group Ltd | Aerosol metering valve |
JP2003502357A (en) * | 1999-06-18 | 2003-01-21 | スリーエム イノベイティブ プロパティズ カンパニー | Steroid solution aerosol products with enhanced chemical stability |
JP4777560B2 (en) * | 1999-06-18 | 2011-09-21 | スリーエム イノベイティブ プロパティズ カンパニー | Steroid solution aerosol products with enhanced chemical stability |
US6610273B2 (en) | 1999-06-18 | 2003-08-26 | 3M Innovative Properties Company | Process for making chemically stable C-17/21 OH 20-ketosteroid aerosol products |
AU777505B2 (en) * | 1999-06-18 | 2004-10-21 | 3M Innovative Properties Company | Steroid solution aerosol products with enhanced chemical stability |
US6315985B1 (en) | 1999-06-18 | 2001-11-13 | 3M Innovative Properties Company | C-17/21 OH 20-ketosteroid solution aerosol products with enhanced chemical stability |
US6967017B1 (en) | 1999-07-23 | 2005-11-22 | Chiesi Farmaceutici S.P.A. | Formulations of steroid solutions for inhalatory administration |
WO2001056639A1 (en) * | 2000-02-02 | 2001-08-09 | Pari GmbH Spezialisten für effektive Inhalation | Inhalation nebulizer |
US8596264B2 (en) | 2000-02-02 | 2013-12-03 | Pari GmbH Spezialisten für effektive Inhalation | Inhalation nebulizer |
US6964759B2 (en) | 2000-02-22 | 2005-11-15 | Chiesi Farmaceutici S.P.A. | Formulations containing an anticholinergic drug for the treatment of chronic obstructive pulmonary disease |
WO2001064524A3 (en) * | 2000-03-01 | 2002-03-28 | Glaxo Group Ltd | Metered dose inhaler |
WO2001064273A3 (en) * | 2000-03-01 | 2002-03-28 | Glaxo Group Ltd | Metered dose inhaler |
WO2001064273A2 (en) * | 2000-03-01 | 2001-09-07 | Glaxo Group Limited | Metered dose inhaler |
WO2001064275A1 (en) * | 2000-03-01 | 2001-09-07 | Glaxo Group Limited | Metered dose inhaler |
WO2001087392A2 (en) | 2000-05-15 | 2001-11-22 | Glaxo Group Limited | Method and package for storing a pressurized container containing a drug |
US7018618B2 (en) | 2000-05-22 | 2006-03-28 | Chiesi Farmaceutici S.P.A. | Stable pharmaceutical solution formulations for pressurized metered dose inhalers |
JP2003534063A (en) * | 2000-05-23 | 2003-11-18 | グラクソ グループ リミテッド | Aerosol container for salmeterol xinafoate formulation |
WO2001098175A1 (en) | 2000-06-20 | 2001-12-27 | Glaxo Group Limited | Method and package for storing a pressurized container containing a drug |
WO2001098176A2 (en) | 2000-06-22 | 2001-12-27 | Glaxo Group Limited | Package for a pressurized container containing a drug |
WO2001097888A2 (en) | 2000-06-22 | 2001-12-27 | Glaxo Group Limited | Method and package for storing a pressurized container containing a drug |
JP2004502719A (en) * | 2000-07-11 | 2004-01-29 | アストラゼネカ・アクチエボラーグ | Novel aerosol formulation containing polar fluorinated molecules |
US7845346B2 (en) * | 2000-08-18 | 2010-12-07 | Norton Healthcare Ltd. | Spray device |
WO2002024552A2 (en) | 2000-09-18 | 2002-03-28 | Glaxo Group Limited | Coated can for a metered dose inhaler |
US6866039B1 (en) | 2000-10-12 | 2005-03-15 | Bespak Plc | Dispensing apparatus |
WO2002047829A1 (en) | 2000-12-13 | 2002-06-20 | Astrazeneca Ab | Surface modification process |
WO2002051483A1 (en) | 2000-12-22 | 2002-07-04 | Glaxo Group Limited | Metered dose inhaler for salmeterol xinafoate |
US7086571B2 (en) | 2001-04-30 | 2006-08-08 | Bespak Plc | Valves for pressurized dispensing containers |
US7696178B2 (en) | 2001-07-02 | 2010-04-13 | Chiesi Farmaceutici S.P.A. | Optimised formulation of tobramycin for aerosolization |
US7939502B2 (en) | 2001-07-02 | 2011-05-10 | Chiesi Farmaceutici S.P.A. | Optimised formulation of tobramycin for aerosolization |
US8168598B2 (en) | 2001-07-02 | 2012-05-01 | Chiesi Farmaceutici S.P.A. | Optimised formulation of tobramycin for aerosolization |
US6945953B2 (en) | 2002-01-22 | 2005-09-20 | Bespak Plc | Dispensing apparatus for delivering powdered product |
WO2005000712A1 (en) * | 2003-06-24 | 2005-01-06 | Cipla Limited | Pharmaceutical dispensing aid |
EP2275479A1 (en) | 2003-08-11 | 2011-01-19 | Glaxo Group Limited | Pharmaceutical metered dose inhaler and methods relating thereto |
US8198354B2 (en) | 2003-08-11 | 2012-06-12 | Glaxo Group Limited | Pharmaceutical metered dose inhaler and methods relating thereto |
WO2005023330A2 (en) | 2003-08-29 | 2005-03-17 | Glaxo Group Limited | Pharmaceutical metered dose inhaler and methods relating thereto |
US7381402B2 (en) | 2004-02-27 | 2008-06-03 | Chiesi Farmaceutici S.P.A. | Stable pharmaceutical solution formulations for pressurized metered dose inhalers |
US8430097B2 (en) | 2007-11-06 | 2013-04-30 | 3M Innovative Properties Company | Medicinal inhalation devices and components thereof |
US8414956B2 (en) | 2007-11-06 | 2013-04-09 | 3M Innovative Properties Company | Medicinal inhalation devices and components thereof |
US8104469B2 (en) | 2007-11-06 | 2012-01-31 | 3M Innovative Properties Company | Medicinal inhalation devices and components thereof |
US8616201B2 (en) | 2007-11-06 | 2013-12-31 | 3M Innovative Properties Company | Medicinal inhalation devices and components thereof |
US8808786B2 (en) | 2007-11-06 | 2014-08-19 | 3M Innovative Properties Company | Medicinal inhalation devices and components thereof |
US10266455B2 (en) | 2007-12-07 | 2019-04-23 | The Sherwin-Williams Company | Coating suitable for medicament contact |
GB2456028A (en) * | 2008-11-14 | 2009-07-01 | Consort Medical Plc | A medicament dispenser with an HFO propellant |
US8815325B2 (en) | 2009-05-06 | 2014-08-26 | 3M Innovative Properties Company | Medicinal inhalation device |
WO2010129758A1 (en) | 2009-05-06 | 2010-11-11 | 3M Innovative Properties Company | Medicinal inhalation devices and components thereof |
US10410838B2 (en) | 2009-05-06 | 2019-09-10 | 3M Innovative Properties Company | Apparatus and method for plasma treatment of containers |
WO2011061498A2 (en) | 2009-11-17 | 2011-05-26 | Cipla Limited | Inhalation solutions |
GB2593970A (en) * | 2020-02-20 | 2021-10-13 | Chiesi Farm Spa | Pressurised metered dose inhalers comprising a buffered pharmaceutical formulation |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU718851B2 (en) | Metered dose inhaler for beclomethasone dipropionate | |
EP1366777B1 (en) | Metered dose inhaler for salmeterol | |
CA2217948C (en) | Metered dose inhaler for fluticasone propionate | |
CA2217950C (en) | Metered dose inhaler for albuterol | |
US20030103906A1 (en) | Metered dose inhaler having internal surfaces coated with fluorocarbon polymer | |
AU751859B2 (en) | Metered dose inhaler for beclomethasone dipropionate | |
AU2002301285B2 (en) | Metered dose inhaler for fluticasone propionate | |
CA2467462A1 (en) | Metered dose inhaler for salmeterol | |
AU4517000A (en) | Metered dose inhaler for salmeterol |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 96194409.9 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN AM AZ BY KG KZ MD RU TJ TM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1996911713 Country of ref document: EP Ref document number: 1199700904 Country of ref document: VN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 306281 Country of ref document: NZ |
|
ENP | Entry into the national phase |
Ref document number: 2218179 Country of ref document: CA Ref document number: 2218179 Country of ref document: CA Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 139197 Country of ref document: SK Ref document number: PA/a/1997/007878 Country of ref document: MX Ref document number: 1019970707250 Country of ref document: KR |
|
ENP | Entry into the national phase |
Ref document number: 1996 531181 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: PV1997-3261 Country of ref document: CZ Ref document number: 08945141 Country of ref document: US Ref document number: 97/01170 Country of ref document: TR Ref document number: 97-01897 Country of ref document: RO Ref document number: 199700230 Country of ref document: EA |
|
WWP | Wipo information: published in national office |
Ref document number: 1996911713 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 1019970707250 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: PV1997-3261 Country of ref document: CZ |
|
WWR | Wipo information: refused in national office |
Ref document number: PV1997-3261 Country of ref document: CZ |
|
WWG | Wipo information: grant in national office |
Ref document number: 1996911713 Country of ref document: EP |
|
WWR | Wipo information: refused in national office |
Ref document number: 1019970707250 Country of ref document: KR |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1996911713 Country of ref document: EP |